Claims:

1. Use of an anti-CD19 antibody in the manufacture of a medicament for treating DLBCL in a patient, wherein the medicament is to be administered in combination with R-CHOP.

2. Use of an anti-CD19 antibody in the manufacture of a medicament for treating DLBCL in a patient, wherein the medicament is to be administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone.

3. The use of claim 2, wherein the patient is to be administered in at least one 21-day cycle a combination of:

the anti-CD19 antibody on day 1, day 8, and day 15 of the 21-day cycle;
rituximab on day 1 of the 21-day cycle;
cyclophosphamide on day 1 of the 21-day cycle;
doxorubicin on day 1 of the 21-day cycle;
vincristine on day 1 of the 21-day cycle; and
prednisone or prednisolone on each of days 1 to 5 of the 21-day cycle.

4. The use according to claim 3, wherein the patient is to be administered at least three 21-day cycles of the combination.

5. The use according to claim 3, wherein the patient is to be administered at least six 21-day cycles of the combination.

6. The use according to claim 2, wherein the patient is to be administered a combination of:

the anti-CD19 antibody;
rituximab in a 375 mg/m^2 dose;
cyclophosphamide in a 750 mg/m^2 dose;
doxorubicin in a 50 mg/m^2 dose;
vincristine in a 1.4 to 2.0 mg/m^2 dose; and
prednisone or prednisolone in a 100 mg dose.

7. The use according to claim 5, wherein the patient is to be administered in at least one 21-day cycle a combination of:

the anti-CD19 antibody on day 1, day 8, and day 15 of the 21-day cycle;

rituximab in a 375 mg/m^2 dose on day 1 of the 21-day cycle;

cyclophosphamide in a 750 mg/m^2 dose on day 1 of the 21-day cycle;

doxorubicin in a 50 mg/m^2 dose on day 1 of the 21-day cycle;

vincristine in a 1.4 to 2.0 mg/m^2 dose on day 1 of the 21-day cycle; and

prednisone or prednisolone in a 100 mg dose on each of days 1 to 5 of the 21-day cycle.

8. The use according to claim 7, wherein the patient is to be administered at least three 21-day cycles of the combination.

9. The use according to claim 7, wherein the patient is to be administered at least six 21-day cycles of the combination.

10. The use according to any one of the preceding claims, wherein the anti-CD19 antibody is to be administered in a body weight dose of 8 mg/kg to 40 mg/kg.

11. The anti-use according to claim 9, wherein the anti-CD19 antibody is to be administered in a body weight dose of 12 mg/kg.

12. The use according to any one of the preceding claims, wherein the treatment further comprises lenalidomide.

13. The use according to claim 12, wherein lenalidomide is to be administered in a 25 mg dose.

14. The use according to claim 12, wherein lenalidomide is to be administered to the patient in at least one 21-day cycle in a 25 mg dose on each of days 1 to 10 of the 21-day cycle.

15. The use according to any one of the preceding claims, wherein the treatment further comprises granulocyte colony stimulating factor (G-CSF) or pegylated G-CSF.

16. The use according to any one of the preceding claims, wherein administration of the combination leads to a complete response (CR) in the patient.

17. The use according to any one of the preceding claims, wherein the antibody comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence SYVMH (SEQ ID NO:1);

the VH CDR2 comprises the amino acid sequence NPYNDG (SEQ ID NO:2); and

the VH CDR3 comprises the amino acid sequence GTYYYGTRVFDY (SEQ ID NO:3); and

wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4);

the VL CDR2 comprises the amino acid sequence RMSNLNS (SEQ ID NO:5); and

the VL CDR3 comprises the amino acid sequence MQHLEYPIT (SEQ ID NO:6).

18. The use according to claim 17, wherein the VH domain comprises the amino acid sequence
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYND
GTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWG
QGTLVTVSS (SEQ ID NO:7) and the VL domain comprises the amino acid sequence
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMS
NLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO:8).

19. The use according to claim 18, wherein the anti-CD19 antibody comprises a heavy chain region of

EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYI
NPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVF
DYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
CDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFN

WYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAP
EEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
NYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP
GK (SEQ ID NO:11) and a light chain region of
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMS
NLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIKRTVA
APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:12).

20. The use according to any one of the preceding claims, wherein the patient has previously untreated DLBCL.

21. The use according to any one of the preceding claims, wherein the patient has an International Prognostic Index (IPI) status of 2-5, 3-5, 4-5, 3-4, 3, 4, or 5 prior to starting the treatment.

22. The use according to any one of the preceding claims, wherein the patient has Stage III or Stage IV DLBCL prior to starting the treatment.

23. The use according to any one of the preceding claims, wherein the anti-CD19 antibody is tafasitamab.

24. Use of an anti-CD19 antibody in the manufacture of a medicament for treating a non-Hodgkin lymphoma, chronic lymphocytic leukemia, or acute lymphoblastic leukemia in a human subject in need thereof, wherein the medicament is to be administered in combination with lenalidomide and rituximab.

25. The use according to claim 24, wherein the antibody comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence SYVMH (SEQ ID NO:1);

the VH CDR2 comprises the amino acid sequence NPYNDG (SEQ ID NO:2); and

the VH CDR3 comprises the amino acid sequence GTYYYGTRVFDY (SEQ ID NO:3); and

wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4);

the VL CDR2 comprises the amino acid sequence RMSNLNS (SEQ ID NO:5); and

the VL CDR3 comprises the amino acid sequence MQHLEYPIT (SEQ ID NO:6).

26. The use according to claim 25, wherein the VH domain comprises the amino acid sequence EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYND GTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWG QGTLVTVSS (SEQ ID NO:7) and the VL domain comprises the amino acid sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMS NLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO:8).

27. The use according to claim 26, wherein the anti-CD19 antibody comprises a heavy chain region of

EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYI NPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVF DYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFN WYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAP EEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK (SEQ ID NO:11) and a light chain region of DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMS NLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIKRTVA APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:12).

28. The use according to any one of claims 24 to 26, wherein the human subject has a non-Hodgkin lymphoma.

29. The use according to claim 28, wherein the non-Hodgkin lymphoma is follicular lymphoma.

30. The use according to claim 29, wherein the follicular lymphoma is relapsed/refractory follicular lymphoma.

31. The use according to claim 29 or 30, wherein the follicular lymphoma is histologically confirmed Grade 1, 2, or 3a follicular lymphoma.

32. The use according to claim 28, wherein the non-Hodgkin lymphoma is marginal zone lymphoma.

33. The use according to claim 32, wherein the marginal zone lymphoma is relapsed/refractory marginal zone lymphoma.

34. The use according to claim 32 or 33, wherein the marginal zone lymphoma is histologically confirmed nodal marginal zone lymphoma, splenic marginal zone lymphoma, or extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue.

35. The use according to claim 28, wherein the non-Hodgkin lymphoma is diffuse large B-cell lymphoma.

36. The use according to claim 35, wherein the diffuse large B-cell lymphoma is relapsed/refractory diffuse large B-cell lymphoma.

37. The use according to claim 28, wherein the non-Hodgkin lymphoma is small lymphocytic lymphoma.

38. The use according to claim 28, wherein the non-Hodgkin lymphoma is mucosa-associated lymphoid tissue lymphoma.

39. The use according to claim 28, wherein the non-Hodgkin lymphoma is Burkitt's lymphoma.

40. The use according to claim 28, wherein the non-Hodgkin lymphoma is mantle cell lymphoma.

41. The use according to any one of claims 24 to 27, wherein the human subject has chronic lymphocytic leukemia.

42. The use according to any one of claims 24 to 27, wherein the human subject has acute lymphoblastic leukemia.

43. The use according to any one of claims 24 to 42, wherein the antibody is to be administered intravenously.

44. The use according to any one of claims 24 to 42, wherein the antibody is to be administered intravenously at a dose of 12 mg/kg.

45. The use according to any one of claims 24 to 42, wherein the antibody is to be administered intravenously at least once every two weeks at a dose of 12 mg/kg.

46. The use according to any one of claims 24 to 42, wherein the antibody is to be administered intravenously at a dose of 12 mg/kg according to the following schedule:

on days 1, 8, 15, and 22 of a first 28-day cycle;

on days 1, 8, 15, and 22 of a second 28-day cycle;

on days 1, 8, 15, and 22 of a third 28-day cycle; and

on days 1 and 15 of a fourth 28-day cycle and on days 1 and 15 of further 28-day cycles thereafter.

47. The use according to any one of claims 24 to 46, wherein rituximab is to be administered intravenously.

48. The use according to any one of claims 24 to 46, wherein rituximab is to be administered intravenously at a dose of 375 mg/m^2.

49. The use according to any one of claims 24 to 46, wherein rituximab is to be administered intravenously at a dose of 375 mg/m^2 according to the following schedule:

on days 1, 8, 15, and 22 of a first 28-day cycle; and

on day 1 of a second 28-day cycle and on day 1 of further 28-day cycles thereafter.

50. The use according to any one of claims 24 to 49, wherein lenalidomide is to be administered orally.

51. The use according to any one of claims 24 to 49, wherein lenalidomide is to be administered orally at a dose of 20 mg.

52. The use according to any one of claims 24 to 49, wherein lenalidomide is to be administered orally at a dose of 20 mg on days 1-21 of repeated 28-day cycles.

53. Use of an anti-CD19 antibody and use of R-CHOP for the preparation of a pharmaceutical combination for the treatment of patients with DLBCL.

54. The use according to claim 53 wherein the pharmaceutical combination is to be administered to the patient in a therapeutic amount of:

an anti-CD19 antibody;

rituximab;

cyclophosphamide;

doxorubicin;

vincristine; and

prednisone or prednisolone.